Stock NAMS FRAZIER LIFESCIENCES ACQUISITION CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Financials Frazier Lifesciences Acquisition Corporation

Equities

NAMS

NL00150012L7

Biotechnology & Medical Research

Real-time Estimate Tradegate
Other stock markets
 10:13:34 29/05/2024 pm IST 		5-day change 1st Jan Change
17.65 EUR -9.07% Intraday chart for Frazier Lifesciences Acquisition Corporation -0.36% +73.77%
16/05 Transcript : NewAmsterdam Pharma Company N.V. - Special Call
15/05 TD Cowen Starts NewAmsterdam Pharma With Buy Rating MT

Valuation

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Capitalization 1 - 830.7 833.1 1,606 - -
Enterprise Value (EV) 1 - 392.2 833.1 1,606 1,606 1,606
P/E ratio -3.39 x -10.6 x -5.1 x -7.73 x -12.4 x -12.6 x
Yield - - - - - -
Capitalization / Revenue - 8.52 x 64.1 x 190 x 255 x 103 x
EV / Revenue - 8.52 x 64.1 x 190 x 255 x 103 x
EV / EBITDA - - - - - -
EV / FCF - 104 x -6.39 x -9.1 x -12.8 x -11.2 x
FCF Yield - 0.96% -15.6% -11% -7.83% -8.92%
Price to Book - 1.71 x - - - -
Nbr of stocks (in thousands) - 81,560 82,324 89,986 - -
Reference price 2 8.575 10.19 10.12 17.85 17.85 17.85
Announcement Date 04/08/22 31/03/23 28/02/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Net sales 1 - 97.5 13.01 8.448 6.296 15.65
EBITDA - - - - - -
EBIT 1 - -6.96 -168.9 -184 -154.9 -159.3
Operating Margin - -7.14% -1,298.56% -2,178.33% -2,459.82% -1,017.98%
Earnings before Tax (EBT) 1 - -78.05 -163.3 -204.5 -130.2 -138
Net income 1 -28.6 -78.05 -163.3 -207.6 -133.8 -137
Net margin - -80.05% -1,255.76% -2,456.87% -2,124.2% -875.39%
EPS 2 -2.530 -0.9600 -1.984 -2.308 -1.440 -1.421
Free Cash Flow 1 - 7.959 -130.4 -176.6 -125.7 -143.3
FCF margin - 8.16% -1,002.43% -2,090% -1,996.63% -915.46%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 04/08/22 31/03/23 28/02/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2022 S2 2023 S1 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 4 9.562 1.304 1.106 1.83 4.546 - -
EBITDA - - - - - - - -
EBIT 1 - - -51.63 -49.82 -45.11 -38.21 -39.59 -35.17
Operating Margin - - -3,960.17% -4,506.55% -2,464.41% -840.48% - -
Earnings before Tax (EBT) 1 - - -93.77 -46.31 -40.78 -35.19 -35.3 -30.85
Net income 1 - -75.1 -93.77 -47.16 -41.21 -35.93 -35.3 -30.85
Net margin - -785.42% -7,192.76% -4,265.9% -2,251.51% -790.28% - -
EPS 2 - -0.9200 -0.9863 -0.5257 -0.4546 -0.3940 -0.3873 -0.3353
Dividend per Share - - - - - - - -
Announcement Date 31/03/23 07/08/23 08/05/24 - - - - -
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Net Debt - - - - - -
Net Cash position - 439 - - - -
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 - 7.96 -130 -177 -126 -143
ROE (net income / shareholders' equity) - -29.2% - - - -
ROA (Net income/ Total Assets) - - - - - -
Assets 1 - - - - - -
Book Value Per Share - 5.940 - - - -
Cash Flow per Share - 0.1000 - - - -
Capex 1 - 0.01 0.02 0.92 1.85 2.77
Capex / Sales - 0.01% 0.17% 10.94% 29.37% 17.72%
Announcement Date 04/08/22 31/03/23 28/02/24 - - -
1EUR in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Frazier Lifesciences Acquisition Corporation

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
17.85 EUR
Average target price
32.12 EUR
Spread / Average Target
+79.98%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
FRAZIER LIFESCIENCES ACQUISITION CORPORATION Stock Frazier Lifesciences Acquisition Corporation
+73.77% 1.75B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+8.83% 115B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+9.88% 105B
BIONTECH SE Stock BioNTech SE
-13.05% 22.71B
ARGENX SE Stock argenx SE
+2.21% 21.83B
GENMAB A/S Stock Genmab A/S
-10.88% 18.18B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.90% 16.52B
BEIGENE, LTD. Stock BeiGene, Ltd.
-16.11% 16.01B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+1.31% 14.14B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+17.47% 10.71B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. NAMS Stock
  4. Financials Frazier Lifesciences Acquisition Corporation